Karin Vanderkerken

Karin Vanderkerken

UNVERIFIED PROFILE

Are you Karin Vanderkerken?   Register this Author

Register author
Karin Vanderkerken

Karin Vanderkerken

Publications by authors named "Karin Vanderkerken"

Are you Karin Vanderkerken?   Register this Author

100Publications

1925Reads

20Profile Views

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma.

Front Genet 2019 15;10:740. Epub 2019 Aug 15.

Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2019.00740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704229PMC
August 2019

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response.

Front Oncol 2018 11;8:566. Epub 2018 Dec 11.

Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2018.00566DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297718PMC
December 2018

The genetic landscape of 5T models for multiple myeloma.

Sci Rep 2018 10 9;8(1):15030. Epub 2018 Oct 9.

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussel, 1090, Belgium.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-33396-w
Publisher Site
http://dx.doi.org/10.1038/s41598-018-33396-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177465PMC
October 2018

Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function?

Mol Immunol 2018 09 25;101:521-526. Epub 2018 Aug 25.

Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center, Ghent University, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2018.08.019DOI Listing
September 2018

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?

Leukemia 2018 07 22;32(7):1500-1514. Epub 2018 Feb 22.

Department Hematology- Stem Cell Laboratory, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0061-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035148PMC
July 2018

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects.

Oncoimmunology 2018 23;7(10):e1484981. Epub 2018 Jul 23.

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussel, Belgium.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/2162402X.2018.1
Publisher Site
http://dx.doi.org/10.1080/2162402X.2018.1484981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169579PMC
July 2018

Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

Oncotarget 2018 04 27;9(32):22871. Epub 2018 Apr 27.

Department of Structural Biology Research Center (SBRC), Research Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Flanders Institute for Biotechnology (VIB), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978272PMC
April 2018

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

Oncotarget 2017 Aug 24;8(32):52016-52025. Epub 2017 May 24.

Department of Structural Biology Research Center (SBRC), Research Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Flanders Institute for Biotechnology (VIB), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581009PMC
August 2017

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.

J Pathol 2017 03 30;241(4):534-546. Epub 2017 Jan 30.

Laboratory of Haematology and Immunology, Myeloma Centre Brussels, Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4860DOI Listing
March 2017

A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.

Clin Cancer Res 2016 Sep 30;22(17):4341-9. Epub 2016 Mar 30.

Institute of Pathology, University of Würzburg, Germany, and Comprehensive Cancer Center Mainfranken (CCCMF), Würzburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-3111DOI Listing
September 2016

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.

Cancer Lett 2016 07 19;377(1):17-24. Epub 2016 Apr 19.

Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium; Stem Cell Laboratory-Division Clinical Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2016.04.024DOI Listing
July 2016

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.

Oncotarget 2016 Jun;7(25):38927-38945

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussels (VUB), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.7792DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122441PMC
June 2016

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

Oncotarget 2016 Apr;7(17):23128-40

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.7440DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029615PMC
April 2016

Novel strategies to target the ubiquitin proteasome system in multiple myeloma.

Oncotarget 2016 Feb;7(6):6521-37

Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.6658DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872730PMC
February 2016

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.

Br J Haematol 2014 Dec 21;167(5):651-63. Epub 2014 Aug 21.

Department of Haematology and Immunology, Myeloma Centre Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium; Department of Biology, Faculty of Science and Technology, Hebron University, Hebron, Palestine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13092DOI Listing
December 2014

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.

Front Oncol 2014 8;4:349. Epub 2014 Dec 8.

Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel , Brussels , Belgium ; Laboratory of Myeloid Cell Immunology, VIB , Brussels , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00349DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258607PMC
December 2014

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

PLoS One 2013 6;8(11):e79752. Epub 2013 Nov 6.

Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, P.R.China ; Stem Cell Laboratory-Division Clinical Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium ; Department of Hematology and Immunology-Vrije Universiteit Brussel (VUB), Myeloma Center Brussels, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0079752PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819242PMC
August 2014

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

Blood 2014 Jul 13;124(4):555-66. Epub 2014 Jun 13.

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-03-562439DOI Listing
July 2014

Cancer associated fibroblasts and tumor growth: focus on multiple myeloma.

Cancers (Basel) 2014 Jun 27;6(3):1363-81. Epub 2014 Jun 27.

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Brussels 1090, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers6031363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190545PMC
June 2014

Vorinostat-induced bone loss might be related to drug toxicity.

Bone 2013 Dec 30;57(2):384-5. Epub 2013 Aug 30.

Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, PR China; Stem Cell Laboratory-Division Clinical Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium; Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Myeloma Center Brussels, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2013.08.024DOI Listing
December 2013

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

Mol Cancer Ther 2013 Sep 5;12(9):1763-73. Epub 2013 Jul 5.

Corresponding Author: Karin Vanderkerken, Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0123DOI Listing
September 2013

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.

Acta Pharmacol Sin 2013 May 8;34(5):699-709. Epub 2013 Apr 8.

Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/aps.2012.182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002867PMC
May 2013

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.

Cancers (Basel) 2013 Apr 15;5(2):430-61. Epub 2013 Apr 15.

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussel, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers5020430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730337PMC
April 2013

Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.

Biochem Biophys Res Commun 2012 Nov 27;428(4):518-24. Epub 2012 Oct 27.

Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0006291X120204
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2012.10.071DOI Listing
November 2012

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.

Dis Model Mech 2012 Nov;5(6):763-71

Department of Genetics and Molecular Biology, Medical School of Xi'an Jiaotong University, Xi'an, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/dmm.008961DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484859PMC
November 2012

In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.

Biochem Biophys Res Commun 2012 Aug 6;424(3):391-7. Epub 2012 Jul 6.

Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, 300052 Tianjin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2012.06.118DOI Listing
August 2012

Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.

Stem Cells 2012 Feb;30(2):266-79

Stem Cell Laboratory, Division of Clinical Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/stem.787
Publisher Site
http://dx.doi.org/10.1002/stem.787DOI Listing
February 2012

Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.

Blood 2012 Jan 29;119(3):826-37. Epub 2011 Nov 29.

Department of Genetics and Molecular Biology, Medical School of Xi'an Jiaotong University, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-07-366492DOI Listing
January 2012

The microenvironment and molecular biology of the multiple myeloma tumor.

Adv Cancer Res 2011 ;110:19-42

Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-386469-7.00002-5DOI Listing
October 2011

The effects of forodesine in murine and human multiple myeloma cells.

Adv Hematol 2010 19;2010:131895. Epub 2010 Oct 19.

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2010/131895DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963119PMC
July 2011

An improved harvest and in vitro expansion protocol for murine bone marrow-derived mesenchymal stem cells.

J Biomed Biotechnol 2010 20;2010:105940. Epub 2010 Dec 20.

Stem Cell Laboratory, Division Clinical Hematology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2010/105940DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010643PMC
April 2011

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.

J Bone Miner Res 2010 Dec 7;25(12):2633-46. Epub 2010 Jun 7.

Mellanby Centre for Bone Research, Department of Human Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.142DOI Listing
December 2010

Large double copy vectors are functional but show a size-dependent decline in transduction efficiency.

J Biotechnol 2010 Oct 16;150(1):37-40. Epub 2010 Jul 16.

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbiotec.2010.07.010DOI Listing
October 2010

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Blood 2010 Sep 7;116(9):1524-7. Epub 2010 Jun 7.

Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-02-269126DOI Listing
September 2010

Thymosin beta4 in multiple myeloma: friend or foe.

Ann N Y Acad Sci 2010 Apr;1194:125-9

Department of Hematology, CHU University of Liège, Liège, Belgium.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1749-6632.2010.05470.x
Publisher Site
http://dx.doi.org/10.1111/j.1749-6632.2010.05470.xDOI Listing
April 2010

Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo.

Hepatology 2010 Feb;51(2):603-14

Department of Cell Biology, Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.23334DOI Listing
February 2010

In search of the most suitable lentiviral shRNA system.

Curr Gene Ther 2009 Jun;9(3):192-211

Laboratory for Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
June 2009

The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.

Arch Physiol Biochem 2009 May;115(2):49-57

Myeloma Research Centre, Brussels, Department of Hematology and Immunology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13813450902736583DOI Listing
May 2009

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

J Bone Miner Res 2009 Mar;24(3):425-36

Academic Unit of Bone Biology, Section of Musculoskeletal Sciences, University of Sheffield School of Medicine and Biomedical Sciences, Sheffield, Yorkshire, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1359/jbmr.081104DOI Listing
March 2009

Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.

Biochem Biophys Res Commun 2008 Dec 16;377(2):453-457. Epub 2008 Oct 16.

Academic Unit of Bone Biology, University of Sheffield, School of Medicine and Biomedical Science, Beech Hill Road, Sheffield S10 2RX, UK. Electronic address:

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0006291X0801944
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2008.09.157DOI Listing
December 2008

Multiple myeloma--an update on diagnosis and treatment.

Eur J Haematol 2008 Nov 13;81(5):329-43. Epub 2008 Sep 13.

Department of Clinical Hematology, Cliniques Universitaires St-Luc, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2008.01127.xDOI Listing
November 2008

Extravasation and homing mechanisms in multiple myeloma.

Clin Exp Metastasis 2008 19;25(4):325-34. Epub 2007 Oct 19.

Department Haematology and Immunology (HEIM), Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-007-9108-4DOI Listing
August 2008

Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.

Bull Cancer 2008 Mar;95(3):301-13

Laboratory of Hematology and Immunology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Jette, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2008.0600DOI Listing
March 2008

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.

Int J Cancer 2007 Apr;120(8):1657-63

Institute of Musculoskeletal Sciences and the Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.22478DOI Listing
April 2007

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.

Clin Exp Metastasis 2006 3;23(5-6):291-300. Epub 2006 Nov 3.

Department of Hematology and Immunology, Vrije Universiteit Brussel-VUB, Laarbeeklaan 103, 1090 Brussels, Belgium,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-006-9038-6DOI Listing
February 2007

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.

Cancer Res 2007 Jan;67(1):202-8

Academic Unit of Bone Biology, Division of Clinical Sciences (South), University of Sheffield Medical School, Beech Hill Road, Sheffield, Yorkshire, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-1287DOI Listing
January 2007

Ac-SDKP: linking cardiac remodeling to hematological malignancies.

Leuk Lymphoma 2006 Sep;47(9):1732-3

Department of Hematology and Immunology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Jette, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190600727780DOI Listing
September 2006

Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.

Haematologica 2006 Feb;91(2):200-6

Department Hematology-Immunology, Vrije Universiteit Brussel, aarbeeklaan 101, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
February 2006

The 5T2MM murine model of multiple myeloma: maintenance and analysis.

Methods Mol Med 2005 ;113:191-205

Department of Hematology and Immunology, Free University Brussels, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1385/1-59259-916-8:191DOI Listing
July 2005

Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.

Haematologica 2005 Jun;90(6):810-7

Department of Pathobiology, Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave., NB40, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
June 2005

Myeloma cells (5TMM) and their interactions with the marrow microenvironment.

Blood Cells Mol Dis 2004 Sep-Oct;33(2):111-9

Department of Hematology and Immunology, Vrije Universiteit Brussel-VUB, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcmd.2004.04.012DOI Listing
February 2005

Part of the multiple myeloma-associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model.

Virchows Arch 2004 Oct 30;445(4):389-95. Epub 2004 Jun 30.

Department of Pathology, University of Antwerp, Wilrijkstraat 10, B-2650 Edegem, Belgium.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00428-004-1064-7
Publisher Site
http://dx.doi.org/10.1007/s00428-004-1064-7DOI Listing
October 2004

Evidence of a role for RANKL in the development of myeloma bone disease.

Curr Opin Pharmacol 2004 Aug;4(4):340-6

Bone Biology Group, G Floor, Division of Clinical Sciences, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2004.03.011DOI Listing
August 2004

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

Blood 2004 Apr 26;103(8):3131-7. Epub 2003 Nov 26.

Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-08-2946DOI Listing
April 2004

Multiple myeloma biology: lessons from the 5TMM models.

Immunol Rev 2003 Aug;194:196-206

Vrije Universiteit Brussel, Department of Hematology and Immunology, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1034/j.1600-065x.2003.00035.xDOI Listing
August 2003

Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.

Cancer Res 2003 Jun;63(12):3019-20

Department of Hematology and Immunology, Vrije Universiteit Brussel-VUB, B-1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
June 2003